Airo National Research Journal
Peer Reviewed Multidisciplinary Indexed Journal
ISSN: 2321-3914
Volume:16 Issue:3 December 2018

Process of Simulation of the Spread of HBV Disease

Mr. Saroj Sarkar
Research Scholar
sarojsarkar89@gmail.com

Abstract

Using An SEIR Model With A Constant Vaccination Rate, This Paper Investigates The Global Behavior Of HBV Spread. Infectivity During The Incubation Period Is Thought To Be A Second Mode Of Transmission.

The Infectivity During The Incubation Period Is Considered As A Second Way Of Transmission Using A SEIR Model With A Constant Vaccination Rate The Basic Reproduction Number R0 Is Calculated From The Two Contact Rates B1 And 2.

Hepatitis B Is An Infectious Disease That Affects The Liver And Is Caused By The Hepatitis B Virus (HBV). In This Paper, We Develop A Hepatitis B Model To Investigate Hepatitis B Transmission Dynamics In Xinjiang, China. The Epidemic Model Involves A Vertical Transmission And An Exponential Birth Rate.

Keywords: HBV Disease, Model Formulation, Model Application.

1. Introduction

The HBV Virus Is A Serious Public Health Issue. In Their Lifetime, Around A Third Of The World's Population, Or Approximately 2 Billion People, Become Infected With The Hepatitis B Virus. Around 360 Million People Are Chronically Infected With HBV, With The Majority Of Them Unaware Of Their Status [1]. And Roughly 20% To 30% Of Them Will Eventually Succumb To Chronic Sequelae. HBV Infection Prevalence Varies By Country, Depending On A Complex Mix Of Behavioral, Environmental, And Host Factors [2]. In People With Chronic HBV Infection, Constant HBV Can Lead To Hepatocellular Carcinoma After 20 Years; The Risk Of Dying Prematurely From Cirrhosis Or Hepatocellular Carcinoma Is 15% To 25% [3].

Clinical Observations And Statistics Show That HBV Can Be Transmitted In A Variety Of Ways. In Developing Countries, Blood-To-Blood Products And Shared Syringes Serve As Medical Transmissions For HBV. HBV Can Also Spread Through The Use Of Shared Razors And Brushes. Mosquitoes And Bedbugs Can Also Be Used To Spread The Virus From Person To Person. HBV Has Been Reported To Be Transmitted Between Sexual Partners. Finally, During Pregnancy Or Breast-Feeding, Mothers Might Pass The Infection To Their Children [4].

Hepatitis B Is A Liver Infection Caused By The Hepatitis B Virus That Can Be Life-Threatening (HBV). It Is A Serious Global Health Issue. It Can Lead To Chronic Liver Disease And Infection, As Well As A High Risk Of Death From Cirrhosis Of The Liver, Which Is Becoming More Common. Chronic (Long-Term) Liver Infections Affect Around 240 Million People Worldwide. Every Year, More Than 780,000 People Die As A Result Of The Acute Or Chronic Impacts Of Hepatitis B [1]. It Is Among The Top Five Infectious Diseases In The United States. China: Around 130 Million People Are HBV Carriers, Accounting For Nearly A Third Of Those Infected With The Virus. 30 Million People Are Chronically Infected With HBV, And 300,000 People Die Each Year From HBV-Related Diseases, Accounting For 40 Percent Of HBV-Related Deaths Worldwide [2]. As per Hepatitis B Data Reported By China's Ministry Of Health From January To December 2012, There Were 1,087,086 New Cases, The Highest Among All Infectious Diseases.

2. Model Formulation

One of the signs of hepatitis B is its mind boggling vertical transmission, The Details Of Which Are Unknown. For Simplicity , We Make Some Assumptions That May Capture The Characteristics Of HBV Carrier Prenatal Transmission, Such As

1. Because The Incidence Of Intrauterine Infection Is Very Low, We Only Consider HBV Carrier Vertical Transmission During Delivery And After Birth.
2. Because The Acute Stage Of HBV Infection Is Relatively Brief In Comparison To The Pregnant Period And The Long Chronic Stage, And Only A Small Percentage Of Children Are Born During The Mother's Acute Infection Period, We Do Not Include Perinatal Infection From Acutely Infected Mothers.
3. Because Many Countries Have Included Hepatitis B Vaccination In Their National Infant Immunization Programmed, We Assume That All Newborns Get Vaccinated At The Same Efficacy, Regardless Of The Risk Of Vertical Infection Being High, Low, Or Zero.
4. In Comparison, For Neonates And Children Younger Than One Year Who Acquire HBV Infection Prenatally, The Risk Of Becoming Chronic Carriers Is Quite High (90 Percent), Especially For Those Born Of Both Hbsag-Positive And Hbeag-Positive Mothers. As A Result, We Categories All Vertically Infected Infants As Chronic Carriers.

We Divide The Whole Population Into Classes Of Susceptible (S), Exposed (E), Acute Infection (I), HBV Carriers (C), And Immunized Based On The Characteristics Of HBV Transmission [6]. (R). A Susceptible Subject Acquires An Acute HBV Infection Through Effective Contact With A Temporary Or Chronic HBV Carrier, Shifts To The Next Compartment (The Latent Period), And, according to the natural history of HBV, it becomes acute HBV for an average of 90 days after that. If the acute infection does not progress chronically, the host removes HBV, recovers, and gains immunity. Acute infections can be followed by years of chronic HBV carriers. Few chronic HBV carriers can eliminate the virus and gain immunity. Both intense contaminations and transporters can spread the sickness in five phases. The model is characterized by the arrangement of common differential conditions displayed beneath.

$$\frac{dS}{dE}=\mu\omega(1-vC)\text{-}\beta(I+\alpha C)S-\mu S,$$

$$\frac{dE}{dt}=\beta(I+\alpha C)S-(\sigma+\mu)E,$$

$$\frac{dI}{dt}=\sigma E-(\gamma_1+\mu)\mathrm{I},$$

$$\frac{dC}{dt}=\mathrm{q}\gamma_1 I-(\gamma_2+\ \mu)C+\mu\omega vC,$$

$$\frac{dR}{dt}=(1-q)\gamma_1 I+\gamma_1 C-\mu R+\mu(1-\omega)$$

The Parameters' Definitions Are Stated Table 2.1. For system & # 40; 2.1 & # 41 ;, the positive octant quadrant R + 5 is invariant in SEICR space. Indeed

$$\frac{dS}{dt}\ |_{s=0}=\mu\omega(E+I+R)+\mu\omega(1-v)C\geq 0$$

E, I, C, And R All Have Comparable Disparities. Since The Overall Population Dipped Below One, $T\rightarrow\infty$, We'll Have A Look At The Following Simplified System.

$$\frac{dS}{dE}=\mu\omega(1-vC)\text{-}\beta(I+\alpha C)S-\mu S,$$

$$\frac{dE}{dt}=\beta(I+\alpha C)S-(\sigma+\mu)E,$$

$$\frac{dI}{dt}=\sigma E-(\gamma_1+\mu)\mathrm{I},$$

$$\frac{dC}{dt}=\mathrm{q}\gamma_1 I-(\gamma_2+\ \mu)C+\mu\omega vC,$$

In The Subset Of Positively Invariant $\mathbb{R}_+^4$

$$\Omega=\{(S,E,I,C)|S,E,I,C\}\geq 0, S+E+I+C\leq\omega$$

Let's Do It This Way For Now.

$$\mathrm{A1}=\mathrm{M}+\Sigma,\mathrm{A2}=\mathrm{M}+\Gamma1,\mathrm{A3}=\mathrm{M}+\Gamma2-\mathrm{M}\omega\mathrm{v},\mathrm{A4}=\mathrm{M}+\Gamma2.$$

The System May Have Two Equilibrium: Disease-free balance and illness balance. P0 =

(S0, E0, I0, C0) = (Ω, 0, 0, 0) and the inherent equilibrium P ∗ = (S^*, E^*, I^*, C^*), where

$$\mathrm{S}^*=\frac{\alpha_1\alpha_2\alpha_3}{\beta\sigma\ (\alpha_3+\alpha\gamma_1 q)}=\frac{\omega}{\rho_0},$$

$$\mathrm{I}^*=(1-\frac{1}{\rho_0})\frac{\omega\mu\sigma\ \alpha_3}{\mu\omega v\sigma q\ \gamma_1+\alpha_1\alpha_2\alpha_3},$$

$$\mathrm{E}^*\frac{\mu+\gamma_1}{\sigma}\mathrm{I}^*,\ \mathrm{C}^*=\frac{q\gamma_1}{\alpha_3}\mathrm{I}^*.$$

The inherent equilibrium is positive and P ∗ is present in all P0> 1. Where the parameters are

$$\rho_0=\frac{\beta\sigma\omega}{(\mu+\sigma)(\mu+\gamma_1)}+\frac{\beta\sigma\alpha q\ \gamma_1\omega}{(\mu+\sigma)(\mu+\gamma_1)(\mu+\gamma_2-\mu\omega v)}$$

If the vertical transmission rates are the same, this is the basic reproduction number obtained from the next generation matrix *Mωvc* It Is Not Thought To Be A New Infection. Conversely, If *Mωvc* We Have Another Basic Reproductive Number If New Infections Are Considered.

$$\mathcal{R}_0=\frac{1}{2}(\frac{\beta\sigma\omega}{(\mu+\sigma)(\mu+\gamma_1)}+\frac{\beta\sigma\alpha q\ \gamma_1\omega}{(\mu+\sigma)(\mu+\gamma_1)(\mu+\gamma_2-\mu\omega v)}+\frac{\mu\omega v}{\mu+\gamma_2}+\sqrt[2]{\Delta}),$$

Where Δ=1(A1a2a4)2(Bωσa4+Bωσαqγ1+Mωva1a2)2-4a1a2a4βωσμων>0. It Is Easy To See That P0=R0 Only When $V = 0$. $P_0 = 1$ Is Equivalent To R0=1, And $P_0 < 1$ If And Only If R0<1. In This Paper, We Take P_0 As Our Basic Reproductive Number.

3. Model Application

This has been demonstrated to be exceptionally powerful in lessening HBV disease. Regardless, in certain pieces of China, for example, western states, country regions and far off regions, there is an earnest need to work on the ideal organization of birth portions for inoculation security and vaccination. People can acquire explicit HBV epidemiological information from the month to month public report on correctable diseases from the Ministry of Health of the People's Republic of China.

The Model Is Being Used To Research HBV Infection In China. In Our Model, We Use Chinese Demographic And Epidemiological Data To Estimate Parameter Values. The Year 2004 Is Assumed To Be The Starting Point. The Least Square Method Compares The Model Simulation With The Statistical Data To Determine The Values Of, A, And The Initial Values E(0), I(0). By Estimation, We Use S(0) = 0.1000 And C(0) = 0.0760. Tables 4.1 And 4.2 Show The Annual New HBV Cases, As Well As The Parameter Values And Initial Values.

Year	2004	2005	2006	2007	2008	2009
Case Number	916426	982297	1109130	1169946	1169569	1179607

Table 4.1. Year wise New Reported HBV Cases.

The Parameter	Value	Unit Source	Parameter	Value	Actual Source
M	0.0131	[26]	*B*	1.1387	LSM

The Parameter	Value	Unit Source	Parameter	Value	Actual Source
V	0.12	[18]	Ω	0.44	Estimated
Σ	7	[29]	A	0.1	LSM
Γ_1	5	[26]	$E(0)$	.119767942e−3	LSM
Γ_2	0.035	[23]	$I(0)$	.769301782e−6	LSM
Q	0.895	[27]			

Table 4.2. Parameter And Initial Values Used In The Numerical Simulations.

P0 = 1.3328 > 1. With The Parameters And Initial Values In Tables 4.1 And 4.2, P0 = 1.3328 > 1. Figure 3 Depicts The Model Simulation Curve Of Annually New HBV Case Numbers And Statistical Data. The Simulation Is Insufficiently Accurate To Match The Real Data, Particularly In 2005 And 2006. The Constant Parameters Could Be The Reason. The Birth Rate, Natural Death Rate, Rate Of Recovery From Acute Infection, And Rate Of Progression To Carrier State Q Are All Assumed To Be Constants. Those Parameters Should Be Functions That Are Age Or Time Dependent. To Get A Better Simulation Result, More Factors That Influence HBV Transmission Should Be Included In The Model. Model simulations show that HBV will survive in China under current precautions, Despite the Results Not Being Accurate Enough.



Figure 3: From 2004 To 2009, There Was A Strong Correlation Between The Simulation Result (Solid Curve) And The Annual Reported Cases (Pentagram), As Well As The Prediction Of New Cases In China From 2010 To 2015.

Figure 4 Shows That Unsuccessful Immunization At Birth Has A Significant Impact On Carriers, Even If It Is Not Apparent Until 2020. As A Result, Immunization At Birth Should Be Improved As Much As Possible To Reduce The Prevalence Of Hb Sag. According To The Simulation In Fig. 4, The Proportion Of Carriers Is Consistent With Data From A 2006 Sampling Survey For HBV Epidemiology, Which Revealed That Carriers Made Up 7.18 Percent Of China's Overall Population.



Fig. 4: Model-Predicted Consequences Of Different Unsuccessful Birth Immunization For HBV Carriers In China From 2004 To 2050, With The Unsuccessful Birth Immunization Parameter = 0.44, 0.34, 0.24, 0.14 (Top To Bottom). The Dynamic Consequence Under The Current Control Measures Is Denoted By The Solid Curve.

As Seen In Fig. 5, And B Have A Significant Impact On The Reproductive Number And Equilibrium. Because HBV Infections In Newborns And Children Are Common In China, And Vaccines Are Effective In Preventing Disease Infection In Infants, We Expect A Significant Reduction In HBV Prevalence And Incidence By Increasing Vaccination Coverage And Effectiveness. In Addition To Immunization At Birth, Lowering The Transmission Coefficient Is An Important Goal That Can Be Accomplished Through Education.



Figure 5: Effects Of The Basic Reproductive Number On The Equilibrium Proportion Of HBV Carriers With Different Unsuccessful Birth Immunization. Effects Of The Transmission Coefficient B On The Basic Reproductive Number With Various Unsuccessful Birth Immunizations (Base Plot). The Unsuccessful Birth Immunization Parameter Is 0.44, 0.24, 0.14 (Top To Bottom) In Both Plots, And The Solid Curves Are Drawn Under The Current Control Measures.

4. Conclusion

In China, The Hepatitis B Virus Is Quite Common, And HBV Control Is A Major Public Health Concern. Hepatitis B Vaccine Use Has Increased, Which Has Had A Significant Impact On HBV Infection Rates And Future HBV-Related Deaths. It Is Difficult To Have Complete Theoretical Analysis Of Existing HBV Models Due To Their High Dimensions, And Most Models Were Generally Studied Numerically. A Detailed Stability And Persistence Analysis Is Investigated For The Model With Perinatal Transmission Prevention Presented In This Paper, And Numerical Simulations are mainly conducted by using Parameter Values Estimated thorugh Demographic And Epidemiological data of China of the perinatal infection prevention model presented in this paper. Basic replica number size P0 Completely Determines The Model's Qualitative

Behaviours, According To Our Findings. Specifically, If 0 1 Is True, At the end of life, it naturally settles into a disease-free equilibrium. Otherwise, the disease persists uniformly and the endemic balance is globally attractive under certain conditions. In addition, the simulation in Figure 2 shows that the endemic balance may be stable globally.

Unlike previous hepatitis models, Our Model's Birth Rate Function Is An Exponential Form Rather Than A Constant. As A Result, This Model's Solutions May "Explode." We Present A Standardization To This Model In Order To Solve This Problem. The Modified Reproductive Number Is Calculated, And It Can Be Used To Determine Whether Or Not The Disease Is Extinct.

Expansion To Immunisation, As Well As Therapeutic Treatment Of Carriers, Such As The Use Of Interferon Or Limousine, Could Be A Very Useful Tool In The Fight Against HBV. In Addition, The Prevention Of Horizontal Transmission Through Vaccination And Behaviour Modification May Have A Significant Impact, Which May Both Be Evaluated In The Model. Because Age May Have Significant Implications For HBV Infection, A Mathematical Model With An Age-Dependent Probability Of Becoming A Carrier State May Be More Reasonable. In This Paper, We Treat It As A Constant Q Due To The Fact That It Occurs In China, But More Precisely, The Probability Should Be An Age-Dependent Function, Resulting In An Age-Structured Model And, Most Likely, A Better Fit To The Data.

5. References

1. *Who, Hepatitis B Fact Sheet No. 204, The World Health Organisation, Geneva, Switzerland, 2013,*
2. *Canadian Centre For Occupational Health And Safety, "Hepatitis B,".*
3. *Healthcare Stumbling In Ri's Hepatitis Fight. The Jakarta Post (2011)*
4. *Medley, G.F., Lindop, N.A., Edmunds, W.J., Nokes, D.J.: Hepatitis-B Virus Endemicity: Heterogeneity, Catastrophic Dynamics And Control. Nat. Med.* ***7****(5), 619–624 (2001)*
5. *Mann, J., Roberts, M.: Modelling The Epidemiology Of Hepatitis B In New Zealand. J. Theor. Biol.* ***269****(1), 266–272 (2011)*
6. *Hepatitis B, (Hbv),*
7. *Cdc, Hepatitis B Virus: A Comprehensive Strategy For Eliminating Transmission In The United States Through Universal Childhood Vaccination. Recommendations Of The Immunization Practices Advisory Committee (Acip). Morb. Mort. Wkly. Rep., Recomm. Rep.* ***40****(Rr-13), 1–25 (1991)*

8. *Libbus, M.K., Phillips, L.M.: Public Health Management Of Perinatal Hepatitis B Virus. Public Health Nursing **26**(4), 353–361 (2009)*
9. *Hollinger, F.B., Lau, D.T.: Hepatitis B: The Pathway To Recovery Through Treatment. Gastroenterol. Clin. North Am. **35**(4), 895–931 (2006)*
10. *Lai, C.-L., Yuen, M.-F.: The Natural History And Treatment Of Chronic Hepatitis B: A Critical Evaluation Of Standard Treatment Criteria And End Points. Ann. Intern. Med. **147**(1), 58–61 (2007)*
11. *Who, Hepatitis B Fact Sheet No. 204, The World Health Organisation, Geneva, Switzerland, 2013,*
12. *Canadian Centre For Occupational Health And Safety, "Hepatitis B,". Healthcare Stumbling In Ri's Hepatitis Fight. The Jakarta Post (2011)*
13. *Medley, G.F., Lindop, N.A., Edmunds, W.J., Nokes, D.J.: Hepatitis-B Virus Endemicity: Heterogeneity, Catastrophic Dynamics And Control. Nat. Med. **7**(5), 619–624 (2001)*
14. *Mann, J., Roberts, M.: Modelling The Epidemiology Of Hepatitis B In New Zealand. J. Theor. Biol. **269**(1), 266–272 (2011)*
15. *Lai, C.-L., Yuen, M.-F.: The Natural History And Treatment Of Chronic Hepatitis B: A Critical Evaluation Of Standard Treatment Criteria And End Points. Ann. Intern. Med. **147**(1), 58–61 (2007)*

Author's Declaration

I as an author of the above research paper/article, hereby, declare that the content of this paper is prepared by me and if any person having copyright issue or patent or anything otherwise related to the content, I shall always be legally responsible for any issue. For the reason of invisibility of my research paper on the website/amendments /updates, I have resubmitted my paper for publication on the same date. If any data or information given by me is not correct I shall always be legally responsible. With my whole responsibility legally and formally I have intimated the publisher (Publisher) that my paper has been checked by my guide (if any) or expert to make it sure that paper is technically right and there is no unaccepted plagiarism and the entire content is genuinely mine. If any issue arise related to Plagiarism / Guide Name / Educational Qualification / Designation/Address of my university/college/institution/ Structure or Formatting/ Resubmission / Submission /Copyright / Patent/ Submission for any higher degree or Job/ Primary Data/ Secondary Data Issues, I will be solely/entirely responsible for any legal issues. I have been informed that the most of the data from the website is invisible or shuffled or vanished from the data base due to some technical fault or hacking and therefore the process of resubmission is there for the scholars/students who finds trouble in getting their paper on the website. At the time of resubmission of my paper I take all the legal and formal responsibilities, If I hide or do not submit the copy of my original documents (Aadhar/Driving License/Any Identity Proof and Address Proof and Photo) in spite of demand from the publisher then my paper may be rejected or removed from the website anytime and may not be consider for verification. I accept the fact that as the content of this paper and the resubmission legal responsibilities and reasons are only mine then the Publisher (Airo International Journal/Airo National Research Journal) is never responsible. I also declare that if publisher finds any complication or error or anything hidden or implemented otherwise, my paper may be removed from the website or the watermark of remark/actuality may be mentioned on my paper. Even if anything is found illegal publisher may also take legal action against me.

Mr. Saroj Sarkar